Plain-English translation of NCT04389281 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This Phase 1 trial is testing X-PACT (X-ray Psoralen Activated Cancer Therapy), a new approach that injects a special medication directly into tumors that can be reached on the skin or near the body's surface, then exposes those tumors to X-ray energy to activate the medication. Researchers want to learn whether this treatment is safe and whether it can help shrink tumors in patients with advanced cancers that haven't responded to standard treatments.
Many patients with advanced cancers run out of effective treatment options or cannot tolerate standard therapies. This trial exists to explore whether directly treating surface tumors with the medication combined with X-rays could offer a new option for these patients.
You likely qualify if…
You likely don't qualify if…
You would receive a series of injections directly into your tumor, followed by exposure to X-rays to activate the medication. In the initial phase, you'd receive five treatments over six weeks (three in week one, one in week two, and a booster in week six), with tumor scans to check progress at weeks 1, 2, 7, and 8. If your tumor responds well, you may be eligible for additional booster treatments spaced 4–6 weeks apart, or even up to 12 more treatments over one year. Throughout the trial, you'll have regular check-ins and imaging to monitor your safety and how well the treatment is working.
AI-generated summary from trial data · Jun 15, 2026 · Not medical advice
United States